1.ADC的设计思路:ADC由三部分组成:细胞毒性药物(术语为‘payload’,有效载荷)、单克隆抗体(mAb)与连接子(Linker)。ADC的主要机制为抗体结合靶抗原、内化后连接子断裂,释放细胞毒性有效载荷。ADC的终极奥义是:最大化肿瘤杀伤、最小化全身毒性。 图1. ADC...
昨天,肺癌国际著名杂志《Lung Cancer》发布了一篇劲爆文章,初步揭示了MET通路异常用PD1可能有奇效的情况。MET通路异常包括点突变(如14跳跃突变等)、扩增、重排和过表达。在肺癌中以MET突变、扩增和过表达多见。该研究中的主要结论有三: 相比MET阴性...
Immunotherapy, which stimulates the body"s immune system to improve the anti-tumor immunity effect, is a new therapeutic method for non-small cell lung cancer (NSCLC). Programmed cell death 1 (PD-1) and its ligand (PD-L1) belong to the CD28/B7 immunoglobulin super-family and are co-...
在2019 年第 20 届世界肺癌大会(World Conference on Lung Cancer,WCLC)上,恒瑞公布了卡瑞利珠单抗非小细胞肺癌的最新临床数据;同时,会议也公布了阿帕替尼的最新进展。 卡瑞利珠单抗进击肺癌一线 此次大会上,恒瑞就卡瑞利珠单抗肺癌领域的 2 项研究做了口头报道,分别是晚期非小细胞肺癌(NSCLC)一线疗法和以基础铂...
肺癌Lung cancer,也称为肺癌lung carcinoma(因为大约 98-99% 的肺癌是癌),是一种恶性肺部肿瘤,其特征是肺组织中的细胞生长不受控制。肺癌来源于转化的恶性细胞,这些细胞起源于上皮细胞,或来源于由上皮细胞组成的组织。其他肺癌,例如罕见的肺部肉瘤,是由间充质细胞产生的结缔组织(即神经、脂肪、肌肉、骨骼)的恶性...
参考文献:Aigner C, Du Pont B, Hartemink K, et al. Surgical outcomes of patients with resectable non-small-cell lung cancer receiving neoadjuvant immunotherapy with nivolumab plus relatlimab or nivolumab: Findings from the prospective, randomized, multicentric phase II study NEOpredict-Lung. ASCO ...
PD-1 is expressed on activated T-cells. Through its ligands, PD-L1 and PD-L2, it suppresses the effector functions mediated by the T-cell receptor [27,29]. In cancer immunotherapy, ICIs, by targeting CTLA-4 or interrupting the PD-1/PD-L1 interaction, can restore immune activity, thereby...
non-small-cell lung cancerPD-1PD-L1/2renal cell carcinomaCancer cells employ several mechanisms to evade the immune system of their host, thus escaping ... KA Reiss,PM Forde,JR Brahmer - 《Immunotherapy》 被引量: 70发表: 2014年 PD-1 blockade: promoting endogenous anti-tumor immunity. The...
HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors 1.从收到稿件到接受稿件用时:4.4个月 Systematic review of the cost-effectiveness of screening for lung cancer with...
Cancer immunotherapies, represented by immune checkpoint inhibitors (ICIs), have reshaped the treatment paradigm for both advanced non-small cell lung cancer and small cell lung cancer. Programmed death receptor-1/programmed death receptor ligand-1 (PD-1